Dmitriy Gennad'EVich Kurbatov

Dmitriy Gennad'EVich Kurbatov

Auto-generated profile, based on publicly available information

Dmitriy Gennad'EVich Kurbatov

Endocrinology Research Centre

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Urology
Verified
Journal Article
Closed access
DKDmitry Kurbatov
Dmitry Kurbatov
Giorgio Ivan RussoGiorgio Ivan Russo
Giorgio Ivan Russo
ALAlexander Lepetukhin
Alexander Lepetukhin
SDSergey Dubsky
Sergey Dubsky
ISIvan Sitkin
Ivan Sitkin
SSSalvatore Sansalone
Salvatore Sansalone

1 August 2015 in Urology
Verified
Journal Article
Closed access
Giorgio Ivan RussoGiorgio Ivan Russo
Giorgio Ivan Russo
DKDmitry Kurbatov
Dmitry Kurbatov
SSSalvatore Sansalone
Salvatore Sansalone
ALAlexander Lepetukhin
Alexander Lepetukhin
SDSergey Dubsky
Sergey Dubsky
Giuseppe MorgiaGiuseppe Morgia
Giuseppe Morgia

6 September 2007 in International Journal Of Impotence Research
Verified
Journal Article
Closed access
DKD G Kurbatov
D G Kurbatov
YKY Y Kuznetsky
Y Y Kuznetsky
SKS V Kitaev
S V Kitaev
VBV A Brusensky
V A Brusensky

20 December 2016 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
IDIvan I. Dedov
Ivan I. Dedov
GMGalina A. Melnichenko
Galina A. Melnichenko
RRRoman V. Rozhivanov
Roman V. Rozhivanov
DKDmitriy G. Kurbatov
Dmitriy G. Kurbatov
Hypogonadism in male patients defined as testosterone level decrease in serum associated with specific symptoms and/or signs (see the detailed description below) can be observed in case of abnormal changes in testes and/or pituitary such as Klinefelter syndrome, Kallmann syndrome and also in male patients with idiopathic, metabolic or iatrogenic disorders resulting in androgen deficiency. The Guidelines does not review all disorders conditioning development of testosterone deficiency (hypogonadism), but focusing on the options of the clinical conditions of hypogonadism generally observed in male patients. This article contains a supplement to the previously published draft of the guidelines: Dedov I.I., Mel’nichenko G.A., Rozhivanov R.V., Kurbatov D.G. The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project. Problems of Endocrinology. 2015;61(5):60-71. doi: 10.14341/probl201561560-71

12 November 2008 in Journal of Andrology
Verified
Journal Article
Open access
PDF file
DKDmitry Kurbatov
Dmitry Kurbatov
JKJury Kuznetsky
Jury Kuznetsky
ATAbdulmaged Traish
Abdulmaged Traish
The goal of this study was to assess the therapeutic benefits of long‐acting testosterone therapy in hypogonadal patients with erectile dysfunction (ED). We recruited 29 patients with ED, ranging in age from 32 to 65 years (mean ± SD, 47 ± 9.7 years), with low plasma testosterone, who did not respond to phosphodiesterase type 5 inhibitor therapy. To evaluate penile arterial and venous blood flow, we employed duplex Doppler ultrasonography. For confirmation of diagnosis of venous leakage, pharmacocavernosography was carried out in 9 patients and magnetic resonance imaging with intracavernous contrast enhancement was carried out in 8 patients. All patients were treated with 1000 mg injectable testosterone undecanoate on day 1, followed by another injection after 6 weeks and every 3 months thereafter, in accordance with Nebido therapy protocol. Plasma testosterone levels were determined in all patients at baseline and after 18 and 30 weeks of testosterone treatment. The International Index of Erectile Function (IIEF‐5) was administered at baseline and after 18 and 30 weeks of testosterone treatment. At baseline total testosterone ranged from 7 to 11.8 nmol/L (200 to 345 ng/dL) in 25 patients. Eighteen and 30 weeks after testosterone treatment, the mean testosterone plasma levels were 18 and 21.5 nmol/L (520 and 625 ng/dL), respectively. After 18 and 30 weeks of testosterone treatment, 20 out of the 29 patients demonstrated marked improvement in erectile function domain, as assessed by the IIEF‐5. This was also associated with diminution of venous leakage. We suggest that, in hypogonadal men with ED, testosterone therapy improves erectile function in patients with ED and venous leakage.

27 December 2017 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
IDIvan I. Dedov
Ivan I. Dedov
GMGalina A. Mel'NIchenko
Galina A. Mel'NIchenko
MSMarina Shestakova
Marina Shestakova
RRRoman V. Rozhivanov
Roman V. Rozhivanov
ATAnna L. Terehova
Anna L. Terehova
DKDmitriy G. Kurbatov
Dmitriy G. Kurbatov
Hypogonadism in men, defined as a reduction in serum testosterone in combination with characteristic symptoms and/or signs (described in detail later), is common in diabetes mellitus (DM). These recommendations do not cover the whole range of pathologies that cause the development of testosterone deficiency (hypogonadism), but focus on its clinical variants and characteristic for men with diabetes. The recommendations provide data on the prevalence of hypogonadism in diabetes, its etiology. In the section "diagnostics" the features of anamnesis of patients with hypogonadism with diabetes, the necessary methods of physical and laboratory examination are presented in detail. The risk factors and clinical consequences of hypogonadism are separately examined. In the section "choice of treatment methods", there are possible treatment options for such patients using various androgenic therapies, taking into account the needs of the man, maintaining his reproductive function and risk factors. Particular attention is paid to indications, contraindications and risk factors for androgen therapy in men with diabetes, especially in old age. With this in mind, principles for monitoring the treatment are developed. Based on a large number of studies, favorable effects of androgen replacement therapy in men with hypogonadism and diabetes have been demonstrated.